Business
GLUCOTRACK ANNOUNCES 90-DAY PRECLINICAL STUDY RESULTS THAT DEMONSTRATE SUSTAINED ACCURACY OF ITS IMPLANTABLE CONTINUOUS BLOOD GLUCOSE MONITOR
Highly accurate continuous blood glucose monitor demonstrates Mean Absolute Relative Difference (MARD) of 4.7% at Day 90 Continuous blood glucose monitor
About this update from Glucotrack, Inc.
[{"type":"text","content":"Highly accurate continuous blood glucose monitor demonstrates Mean Absolute Relative Difference (MARD) of 4.7% at Day 90 Continuous blood glucose monitor offers the potential for simplified, discreet and less intrusive glucose monitoring for people with diabetes Rutherford, NJ, June 05, 2024 (GLOBE NEWSWIRE) -- Glucotrack, Inc. (Nasdaq: GCTK) (“Glucotrack” or the “Company”), a medical technology company focused on the design, development, and commercialization of novel technologies for people with diabetes, today announced that it has successfully completed a second long-term preclinical study for its Continuous Blood Glucose Monitor (CBGM). This study further validates the CBGM’s sustained accuracy and performance with a Mean Absolute Relative Difference (MARD) of 4.7% at Day 90, which is considered highly accurate for a continuous glucose monitor. MARD is a key metric used to assess the accuracy of glucose monitoring devices, measuring the average difference between the CBGM device’s measurement and a reference measurement, most often obtained via capillary blood glucose. Lower values indicate better performance. Glucotrack’s CBGM measures glucose in the blood, without the lag time associated with subcutaneous sensors that measure glucose in interstitial fluid. The ability to directly measure blood glucose in real time and on a continuous basis enables a less burdensome approach to glucose monitoring for extended periods of time. The 90-day preclinical study, which included a larger number of animal subjects and a longer duration than the initial 60-day study announced earlier this year, further validates the CBGM’s sustained accuracy and performance. The study incorporated periodic glucose tolerance testing to compare the performance of the Glucotrack CBGM against both a commercially available blood glucose monitor and a subcutaneous continuous glucose monitor. The study was completed with no significant adverse effects. “We are again very pleased with the performance of our sensor during a long-term preclinical study and look forward to moving into human clinical trials” stated Paul Goode, PhD, CEO of Glucotrack. “Our CBGM’s ability to continuously measure blood glucose for 2+ years with accuracy, minimal calibration and without a wearable device represents a significant advancement in glucose monitoring. We believe this tec...